PT003 MDI Cardiovascular Safety Study

Completed · Phase 2

Conditions studied: Chronic Obstructive Pulmonary Disease

In brief

This study is primarily a safety study. The primary and secondary endpoints are based on 24-hour Holter monitor assessments obtained on Day 14 relative to baseline.

Key facts

Study ID: NCT01349803
Run by: Pearl Therapeutics, Inc.
People needed: 237
Starts: 2011-05-01
Expected to finish: 2011-11-01
Last updated by the study team: 2017-01-31

Who can join

Age: 40 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Pearl Investigative Site — Glendale, Arizona, United States
Pearl Investigative Site — Fullerton, California, United States
Pearl Investigative Site — Los Angeles, California, United States
Pearl Investigative Site — San Diego, California, United States
Pearl Investigative Site — Pensacola, Florida, United States
Pearl Investigative Site — Lafayette, Louisiana, United States
Pearl Investigative Site — North Dartmouth, Massachusetts, United States
Pearl Investigative Site — Livonia, Michigan, United States
Pearl Investigative Site — Medford, Oregon, United States
Pearl Investigative Site — San Antonio, Texas, United States
Pearl Investigative Site — Glebe, New South Wales, Australia
Pearl Investigative Site — Caboolture, Queensland, Australia
Pearl Investigative Site — Dawpark, South Australia, Australia
Pearl Investigative Site — Toorak Gardens, South Australia, Australia
Pearl Investigative Site — Heidelberg, Victoria, Australia
Pearl Investigative Site — Nedlands, Western Australia, Australia
Pearl Investigative Site — Caversham, Dunedin, New Zealand
Pearl Investigative Site — Private Bag, Hamilton, New Zealand
Pearl Investigative Site — Tauranga, North Island, New Zealand
Pearl Investigative Site — Newtown, Wellington Region, New Zealand

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.